Mlakar V, Oehme I, Lesne L, Najafi S, Ansari M, Gumy-Pause F
Front Oncol. 2024; 14:1433256.
PMID: 39717750
PMC: 11664348.
DOI: 10.3389/fonc.2024.1433256.
Pervushin N, Nilov D, Pushkarev S, Shipunova V, Badlaeva A, Yapryntseva M
Apoptosis. 2024; 29(11-12):2197-2213.
PMID: 39222276
PMC: 11550243.
DOI: 10.1007/s10495-024-02014-8.
Pirvu L, Neagu G, Albulescu A, Stefaniu A, Pintilie L
Int J Mol Sci. 2023; 24(8).
PMID: 37108565
PMC: 10139435.
DOI: 10.3390/ijms24087404.
Hou R, Yu Y, Sluter M, Li L, Hao J, Fang J
Cell Rep. 2022; 39(12):111000.
PMID: 35732130
PMC: 9282716.
DOI: 10.1016/j.celrep.2022.111000.
Wang H, Wang X, Xu L, Zhang J
BMC Genom Data. 2022; 23(1):41.
PMID: 35655142
PMC: 9164562.
DOI: 10.1186/s12863-022-01059-5.
p53-Mediated Radiosensitization of Lu-DOTATATE in Neuroblastoma Tumor Spheroids.
Lundsten S, Berglund H, Jha P, Krona C, Hariri M, Nelander S
Biomolecules. 2021; 11(11).
PMID: 34827693
PMC: 8615514.
DOI: 10.3390/biom11111695.
Venetoclax-based Rational Combinations are Effective in Models of -amplified Neuroblastoma.
Dalton K, Krytska K, Lochmann T, Sano R, Casey C, DAulerio A
Mol Cancer Ther. 2021; 20(8):1400-1411.
PMID: 34088831
PMC: 10350345.
DOI: 10.1158/1535-7163.MCT-20-0710.
Hypoxia Predicts Poor Prognosis in Neuroblastoma Patients and Associates with Biological Mechanisms Involved in Telomerase Activation and Tumor Microenvironment Reprogramming.
Cangelosi D, Morini M, Zanardi N, Sementa A, Muselli M, Conte M
Cancers (Basel). 2020; 12(9).
PMID: 32825087
PMC: 7563184.
DOI: 10.3390/cancers12092343.
An overview of neuroblastoma cell lineage phenotypes and models.
Campos Cogo S, Gradowski Farias da Costa do Nascimento T, de Almeida Brehm Pinhatti F, de Franca Junior N, Santos Rodrigues B, Cavalli L
Exp Biol Med (Maywood). 2020; 245(18):1637-1647.
PMID: 32787463
PMC: 7802384.
DOI: 10.1177/1535370220949237.
Functional characterization of full-length BARD1 strengthens its role as a tumor suppressor in neuroblastoma.
Cimmino F, Avitabile M, Lasorsa V, Pezone L, Cardinale A, Montella A
J Cancer. 2020; 11(6):1495-1504.
PMID: 32047556
PMC: 6995383.
DOI: 10.7150/jca.36164.
WDR5 is a conserved regulator of protein synthesis gene expression.
Bryan A, Wang J, Howard G, Guarnaccia A, Woodley C, Aho E
Nucleic Acids Res. 2020; 48(6):2924-2941.
PMID: 31996893
PMC: 7102967.
DOI: 10.1093/nar/gkaa051.
Discovery, characterization and potential roles of a novel NF-YAx splice variant in human neuroblastoma.
Cappabianca L, Farina A, Di Marcotullio L, Infante P, De Simone D, Sebastiano M
J Exp Clin Cancer Res. 2019; 38(1):482.
PMID: 31805994
PMC: 6896337.
DOI: 10.1186/s13046-019-1481-8.
PRIMA-1-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level.
Mlakar V, Jurkovic Mlakar S, Lesne L, Marino D, Rathi K, Maris J
J Exp Clin Cancer Res. 2019; 38(1):69.
PMID: 30755224
PMC: 6373164.
DOI: 10.1186/s13046-019-1066-6.
Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.
Van Goethem A, Yigit N, Moreno-Smith M, Vasudevan S, Barbieri E, Speleman F
Oncotarget. 2017; 8(34):57047-57057.
PMID: 28915653
PMC: 5593624.
DOI: 10.18632/oncotarget.18982.
MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.
Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R
Oncoimmunology. 2017; 6(6):e1316439.
PMID: 28680748
PMC: 5486189.
DOI: 10.1080/2162402X.2017.1316439.
miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.
Mairinger F, Werner R, Flom E, Schmeller J, Borchert S, Wessolly M
Virchows Arch. 2017; 470(6):627-637.
PMID: 28466156
DOI: 10.1007/s00428-017-2133-z.
Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
Veschi V, Liu Z, Voss T, Ozbun L, Gryder B, Yan C
Cancer Cell. 2017; 31(1):50-63.
PMID: 28073004
PMC: 5233415.
DOI: 10.1016/j.ccell.2016.12.002.
The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma.
Mazar J, Rosado A, Shelley J, Marchica J, Westmoreland T
Oncotarget. 2016; 8(4):6589-6607.
PMID: 28035057
PMC: 5351655.
DOI: 10.18632/oncotarget.14244.
Nutlin-3a selects for cells harbouring TP53 mutations.
Kucab J, Hollstein M, Arlt V, Phillips D
Int J Cancer. 2016; 140(4):877-887.
PMID: 27813088
PMC: 5215675.
DOI: 10.1002/ijc.30504.
E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia.
Park I, Blum W, Baker S, Caligiuri M
Leukemia. 2016; 31(2):502-505.
PMID: 27773928
PMC: 5509909.
DOI: 10.1038/leu.2016.293.